Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331381 | 1.00 | EPHX1 (0.32) | EPHX1KDM4EMAPTUSP2ALDH1A1 | |
| SCHEMBL28009506 | 1.00 | EPHX1 (0.32) | EPHX1KDM4EMAPTUSP2ALDH1A1 | |
| SCHEMBL19315953 | 1.00 | EPHX1 (0.32) | EPHX1KDM4EMAPTUSP2ALDH1A1 | |
| SCHEMBL16599675 | 0.97 | KDM4E (0.32) | KDM4EMAPT | |
| SCHEMBL18955033 | 0.97 | KDM4E (0.32) | KDM4EMAPT | |
| SCHEMBL5243316 | 0.95 | KDM4E (0.31) | KDM4EMAPT | |
| SCHEMBL21280953 | 0.92 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL1362200 | 0.92 | EPHX1 (0.33) | EPHX1 | |
| Hydrochloric Acid SCHEMBL3795500 | 0.90 | KDM4E (0.33) | EPHX1KDM4EMAPTLMNABLM | |
| SCHEMBL15547078 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8444954-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060239923-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-10-26 | — | — | US | disclosed |
| US-4832732-A | 1-methyl-1H-imidazole-5-carboxylic acid derivatives and their use as herbicides | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-23 | — | — | US | disclosed |
| EP-0273531-A1 | 1-Methyl-1h-imidazole-5-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239923-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | EPHX1 3582/4885KDM4E 4611/4885MAPT 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.